
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Human Cancer Biology |
Authors' Affiliations: 1 Department of Immunology, School of Basic Medicine, Peking University Center for Human Disease Genomics; Departments of 2 Prosthodontics and 3 Periodontology, School of Stomatology, Peking University; 4 Institute of Hematology, Peking University People's Hospital; and 5 Department of Hemoltology, Peking University First Hospital, Beijing, P.R. China
Requests for reprints: Hongshan Zhao, Department of Immunology, School of Basic Medicine, Peking University Center for Human Disease Genomics, Peking University, 38 Xueyuan Road, 100083 Beijing, P.R. China. Phone: 86-10-82802846, ext. 420; Fax: 86-10-82801149; E-mail: hongshan{at}bjmu.edu.cn.
Purpose: Chronic myelogenous leukemia (CML) is a disease characterized cytogenetically by the presence of the Philadelphia chromosome. Recent studies suggested that altered PDCD5 expression may have significant implications in CML progression. The aim of this study was to identify single-nucleotide polymorphisms (SNP) within the programmed cell death 5 (PDCD5) promoter region and show their functional relevance to PDCD5 expression as well as their genetic susceptibility to CML.
Experimental Design: One hundred twenty-nine CML subjects and 211 healthy controls were recruited for identification of SNPs and subsequent genetic analysis. Luciferase reporter assays were carried out to show the functional significance of the SNPs located in the promoter region to PDCD5 expression. Real-time quantitative PCR and Western blot analysis were done to determine the expression differences of PDCD5 in CML patients with different genotypes.
Results: Two SNPs were identified within the PDCD5 promoter. They are 27A>G and 11G>A (transcription start site as position 1), respectively. The complete linkage disequilibrium was found between these two polymorphisms. The frequencies of 27G+/11A+ genotype and 27G/11A allele were significantly higher in CML patients than in healthy controls (genotype: 26.36% versus 11.85%,
2=11.75, P < 0.01; allele: 13.57% versus 6.40%,
2 = 9.48, P < 0.01). Luciferase reporter assays revealed that the promoter with 27G/11A had significantly lower transcriptional activity and could not be up-regulated after apoptotic stimulations compared with the promoter with 27A/11G. PDCD5 expression analysis in mononuclear cells derived from CML patients and cell lines with different 27/11 genotypes showed consistent results with the reporter assays.
Conclusions: These data suggest that 27G/11A is associated with reduced PDCD5 promoter activity and increased susceptibility to CML.
This article has been cited by other articles:
![]() |
Y. Wang, D. Li, H. Fan, L. Tian, Y. Zhong, Y. Zhang, L. Yuan, C. Jin, C. Yin, and D. Ma Cellular Uptake of Exogenous Human PDCD5 Protein J. Biol. Chem., August 25, 2006; 281(34): 24803 - 24817. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |